Latest Articles

Chronic sleep disruption (CSD) has been shown to promote pain. Now, a team of scientists have shed light on some of the brain regions and signaling molecules that may be responsible, offering potential avenues for therapeutic investigation.

Technology Networks invited Dr. Nigel Jamieson, clinical senior lecturer and honorary hepato-pancreato-biliary surgeon at Glasgow Royal Infirmary, to an Ask Me Anything session to answer your questions about spatial biology.

Martin Farley, sustainable research adviser at UCL and director of Green Lab Associates, was invited to Technology Networks’ Ask Me Anything session to answer your questions about the future of sustainability in research and laboratory practices.

Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.

Bayesian statistics has emerged as a powerful methodology for making decisions from data in the applied sciences. Bayesian brings a new way of thinking to statistics, in how it deals with probability, uncertainty and drawing inferences from an analysis.

The gene therapy landscape is dynamic and constantly shifting. In this article, we will review major advances in disease modification for illnesses that presently still lack effective treatments, as well as some challenges and approaches to overcome them.

Scientists have demonstrated the potential for using intratumoral microdevices (IMDs) to test various cancer drugs on the tumor before implementing systemic treatment. The approach could offer a hope in tackling hard-to-treat gliomas.

Biomarkers can potentially aid patient management across the stages of their disease course. This article will review advances in computationally-driven biomarker discovery, including from metabolomics datasets, for complex, multifactorial diseases.

Ketamine is increasingly used as an antidepressant. A new clinical trial suggests the drug's effects may be may be placebo-based. In this article, we explore what that means for the drug's rollout for ketamine and psychedelic research.

In this article, Mike Hawrylycz, an investigator at the Allen Institute for Brain Science, discusses a large, collaborative quest to discover the different cell types of the brain.